US · Healthcare · Biotechnology
EPS came in at -0.80 against a street estimate of -1.24 — a beat of 35.5%.
Analysts rate Immunic Inc a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $43.09.
| Fund | Stake |
|---|---|
| Aberdeen Group PLC | 6.04% |
| Bvf Inc | 5.61% |
| Millennium Management LLC | 5.43% |
| Avidity Partners Management LP | 4.91% |
| BRAIDWELL LP | 4.73% |
| LAURION CAPITAL MANAGEMENT LP | 4.47% |
| Vanguard Capital Management, LLC | 4.19% |
| Jones Hill Capital LP | 3.96% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Immunic Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.